Loading...
•
Sep 30, 2025
Xeris Biopharma Q3 2025 Earnings Report
Estimated Revenue:$73.5M
+40.1% YoY
Estimated EPS:$0.01
+111.1% YoY
Key Takeaways
Xeris Biopharma generated $74380000 in total revenue for Q3 2025, driven by strong product sales, particularly Recorlev. The company reported positive net income of $621000 and operating income of $6731000, with growth across key products and improved gross margins.
Total revenue grew 37.1% year-over-year to $74380000.
Recorlev revenue of $36975000 grew 108.6% year-over-year.
Company achieved net income of $621000 for the quarter.
Gross margin improvement supported operating leverage and profitability.
Revenue by Segment
Forward Guidance
Management raised full-year 2025 revenue guidance based on Q3 performance and continued growth momentum.
Positive Outlook
- Updated full-year revenue guidance to $285000000–$290000000.
- Strong demand for Recorlev with double-digit growth.
- Adjusted EBITDA improved significantly versus prior year.
- Positive net income achieved for Q3 2025.
- Gross margin improvements support operating leverage.
Challenges Ahead
- R&D expenses increased compared to prior year.
- SG&A expenses grew modestly, reflecting commercial investment.
- Keveyis revenue declined slightly year-over-year.
- Market competition risks remain in rare disease segments.
- Future expense growth anticipated with expanded operations.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...